Navigation Links
Data Show Vaprisol(R) Is Effective & Safe in Promptly Increasing Serum Sodium Levels in Patients With Euvolemic or Hypervolemic Hyponatremia
Date:10/10/2007

DEERFIELD, Ill., Oct. 10 /PRNewswire/ -- Astellas Pharma US, Inc. today announced results of an analysis showing that Vaprisol (conivaptan hydrochloride injection) produced a prompt and sustained (over the 4-day treatment period) increase in serum sodium concentration [Na+] among hospitalized patients with euvolemic and hypervolemic hyponatremia with a low risk of overly rapid [Na+] correction. The study results were presented during the annual meeting of the American College of Emergency Physicians in Seattle.

"Acute hyponatremia is a serious condition that requires immediate medical attention," said Lynne E. Wagoner, MD, Director of Heart Failure, Greater Cincinnati Cardiovascular Consultants. "These data demonstrated that Vaprisol promptly and safely increased [Na+] in patients with euvolemic and hypervolemic hyponatremia."

Vaprisol is the first in a new class of arginine vasopressin (AVP) receptor antagonists. Vaprisol blocks both V1a and V2 vasopressin receptors, resulting in increased urine output without increased sodium loss. This effect, known as "aquaresis," increases serum sodium levels and helps to restore salt and water balance in patients with hyponatremia due to increased body water (dilutional hyponatremia).

Vaprisol is approved by the U.S. Food and Drug Administration as a treatment for euvolemic and hypervolemic hyponatremia in hospitalized patients. Vaprisol is not indicated for the treatment of congestive heart failure. It should only be used for the treatment of hyponatremia in patients with underlying heart failure when the expected benefit of raising serum sodium outweighs the increased risk of adverse events. The approved treatment regimen for Vaprisol starts with a 20 mg loading dose followed by a continuous infusion of 20 mg/day, which may be titrated to 40 mg/day if necessary. The 80 mg/day dose included in this analysis is not an approved dose.

Study Findings

The post-hoc pooled analysis is based on re
'/>"/>

SOURCE Astellas Pharma US
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. New Way to "See" Genes, Evaluate Effectiveness of Gene Therapies Discovered
2. Inhaled Steroids Safe & Effective for Children with Asthma
3. Morning after pill effective up to five days after having unprotected sex
4. Distraction therapy found very effective in postoperative patients
5. ZD1839 Proves Effective - A Breakthrough in fighting Lung Cancer
6. TELITHROMYCIN - the proven effective new drug for cap
7. Foods Rich In Flavonoids Effective In Prevention Of Cough
8. Looking Towards More Effective Leukemia Treatment
9. Effectiveness of acupuncture for migraines
10. PA-824 drug effective against Tuberculosis
11. Milk Thistle Not An Effective Cure For Liver Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/14/2014)... treat children with uncomplicated acute appendicitis is a reasonable ... fewer missed school days, according to a pilot study. ... Hospital and published online April 12 in the ... the first prospective study on nonoperative management of acute ... , Researchers enrolled 77 patients age 7 to 17 ...
(Date:4/14/2014)... 2014, Perth, Australia. Drug discovery company Proteomics International ... of a companion diagnostic (CDx) test with the ... The research team authenticated the panel of biomarkers ... samples. Seven biomarkers were validated at high stringency ... The mass spectrometry data was then cross-validated using ...
(Date:4/14/2014)... 2014) When it comes to the cost and ... Patients get the best care when they are treated ... extensive experience in their current job, according to a ... and Columbia Business School. The study was published in ... Applied Economics . , The review of more ...
(Date:4/13/2014)... STANFORD, Calif. A low-cost empowerment program for ... and sexual harassment of these girls, who live ... and are frequently attacked, a large new study ... Stanford University School of Medicine, Lucile Packard Children,s ... No Worldwide, validated the program,s effectiveness in combating ...
(Date:4/11/2014)... the processes that control brain cell production could pave ... brain-related disorders. , Scientists have gained new understanding of ... how and when nerve and brain cells are formed ... and keeps it healthy. Their findings could help explain ... which is a fundamental characteristic of many diseases including ...
Breaking Medicine News(10 mins):Health News:Antibiotics alone are a successful treatment for uncomplicated acute appendicitis in kids 2Health News:Antibiotics alone are a successful treatment for uncomplicated acute appendicitis in kids 3Health News:Longer nurse tenure on hospital units leads to higher quality care 2Health News:Empowerment program greatly decreases incidence of rape, Stanford/Packard-led study finds 2Health News:Empowerment program greatly decreases incidence of rape, Stanford/Packard-led study finds 3Health News:Empowerment program greatly decreases incidence of rape, Stanford/Packard-led study finds 4
... in Sweden have developed a new drug that can ... // almost 2 million lives annually. Some of the ... encephalopathy. ,The diseases are caused when the ... then accumulate in large amounts, blocking the flow of ...
... name drugs which are taken regularly by older Americans have risen ... 2006, against an inflation rate of 3.8%. The survey was conducted ... Tuesday. It is also reported that the prices of 75 commonly ... of drugs with highest price rise is Aventis' Ambien 5mg with ...
... While you luxuriate in the comfort of your hotel stay, ... getting under your skin! Scientists //have warned that people with ... because everything they touch absorbs the Oh, so friendly virus! ... can spread the virus to an estimated 35% of all ...
... the use of the newer painkillers called COX-2 ... discontinued Vioxx and Bextra.// Old standbys, like ibuprofen ... 2006 issue of the Harvard Heart Letter. The ... but worth being aware of. ,Ibuprofen, aspirin, ...
... get the consent of one or both parents before having ... a Florida State University law professor in Tallahassee, Fla. ... Thomas Stratmann, professor of economics at George Mason University, came ... gonorrhea among teenage girls as a measure of risky sex ...
... as the “strong, silent type” and the stigma of ... likely than women to be referred to studies of ... and express symptoms of depression, according to clinicians and ... Davis Department of Psychiatry and Behavioral Sciences. ,The ...
Cached Medicine News:Health News:Brand Name Drug Prices Zoom 2Health News:Abortion Notification, Consent Laws Reduce Risky Teen Sex 2Health News:Stereotypes Contribute to Older Men Seeking, Receiving Depression Care Less Frequently 2Health News:Stereotypes Contribute to Older Men Seeking, Receiving Depression Care Less Frequently 3Health News:Stereotypes Contribute to Older Men Seeking, Receiving Depression Care Less Frequently 4
(Date:1/15/2014)... , Jan. 15, 2014  Zafgen, Inc., ... unmet needs of severely obese patients, today announced ... beloranib, a selective inhibitor of methionine aminopeptidase 2 ... severe form of genetic obesity.  These results showed ... composition, including reductions in body fat content and ...
(Date:1/14/2014)... HAMILTON, N.J. , Jan. 14, 2014 ... partnering event for buyers and sellers of high-value chemistry, ... annual conference at the Miami Beach ... http://photos.prnewswire.com/prnh/20131028/NY05330LOGO-a ) More than 3,500 ... companies will take part in the conference, which includes ...
(Date:1/14/2014)... Emergency Critical Care, a LifeCentre partner practice, located at 165 Fort ... first in Loudoun County to receive a ... M. Barnes , Medical Director, is a well-seasoned veterinarian of more ... , are avid scuba divers. "As altitude skiers and hikers, we ... states Dr Barnes. She goes on to state "my wish list ...
Breaking Medicine Technology:Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4Media Advisory: InformEx 2014 Events & Speaker Lineup for 30th Edition Conference in Miami Beach 2Hyperbaric Veterinary Medicine (hvm) Announces Animal Emergency Critical Care Installs A Small Animal Hyperbaric Chamber 2
... Mich., Oct. 29 Perrigo Company (Nasdaq: PRGO;TASE) today ... dividend of $0.0625 per share, payable on December 15, ... The new quarterly dividend of $0.0625 per share ... paid in the last four quarters. , Perrigo ...
... HONOLULU, Oct. 29 /PRNewswire-FirstCall/ -- ... ), the global specialty biopharmaceutical company, announced today that it ... treatments, INTUNIV (TM) (guanfacine) Extended Release Tablets, ... and Daytrana ®( ) (methylphenidate transdermal system) ...
Cached Medicine Technology:Shire to Present Important Study Findings on its ADHD Treatments at a Major Psychiatric Meeting on October 29 and 30 2Shire to Present Important Study Findings on its ADHD Treatments at a Major Psychiatric Meeting on October 29 and 30 3Shire to Present Important Study Findings on its ADHD Treatments at a Major Psychiatric Meeting on October 29 and 30 4Shire to Present Important Study Findings on its ADHD Treatments at a Major Psychiatric Meeting on October 29 and 30 5Shire to Present Important Study Findings on its ADHD Treatments at a Major Psychiatric Meeting on October 29 and 30 6Shire to Present Important Study Findings on its ADHD Treatments at a Major Psychiatric Meeting on October 29 and 30 7Shire to Present Important Study Findings on its ADHD Treatments at a Major Psychiatric Meeting on October 29 and 30 8Shire to Present Important Study Findings on its ADHD Treatments at a Major Psychiatric Meeting on October 29 and 30 9
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: